Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2022
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

Managing thyroid disease in women planning pregnancy

Jennifer Yamamoto and Lois E. Donovan
CMAJ July 17, 2017 189 (28) E940; DOI: https://doi.org/10.1503/cmaj.170021
Jennifer Yamamoto
Department of Medicine (Yamamoto, Donovan), Division of Endocrinology and Metabolism; Department of Obstetrics and Gynecology (Donovan), University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lois E. Donovan
Department of Medicine (Yamamoto, Donovan), Division of Endocrinology and Metabolism; Department of Obstetrics and Gynecology (Donovan), University of Calgary, Calgary, Alta.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Lois.Donovan@albertahealthservices.ca
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading

Women with pre-conception hypothyroidism often require increased levothyroxine once they are pregnant

Increasing levothyroxine by two extra dosages per week after pregnancy is confirmed prevents development of overt hypothyroidism among most women.1 Women with a pre-conception thyroid-stimulating hormone (TSH) level of < 1.2 mIU/L usually do not require an increase in levothyroxine once they are pregnant.2 Therefore, we suggest maintaining the pre-conception levothyroxine dose when the pre-conception TSH is < 1.2 mIU/L, with adjustments if indicated by TSH monitoring.

Women should avoid ingesting levothyroxine with iron- or calcium-containing supplements

Both calcium and iron supplements have been shown to interfere with absorption of thyroid hormone.3 Ingestion of iron, calcium or prenatal vitamins should be separated from levothyroxine by at least four hours.3

Rates of conception and live birth are not likely influenced by minor thyroid dysfunction4

Thus, women with subclinical hypothyroidism (Box 1) or positive thyroid antibodies (thyroid peroxidase antibody, thyroglobulin antibody) who are planning pregnancy can be reassured.4 Furthermore, a randomized trial of levothyroxine therapy in women with thyroid peroxidase antibodies did not show a difference in spontaneous abortion or preterm delivery rates.5

Box 1: Definitions for thyroid disorders1
DisorderDescription
Overt hypothyroidismTSH above the upper limit of normal with low free T4 or TSH > 10 mIU/L
Subclinical hypothyroidismTSH above the upper limit of normal but < 10 mIU/L, with normal free T4
  • Note: TSH = thyroid-stimulating hormone.

Women with active Graves disease or toxic adenoma should delay pregnancy until normal thyroid function is established

The maternal and fetal risk and benefits of available therapeutic options (antithyroid drugs, radioactive iodine, thyroidectomy) should be discussed if pregnancy is planned. Women who receive radioactive iodine should allow for clearance of radioactivity before conceiving (6 months).1

Propylthiouracil is preferred for antithyroid drug treatment before conception

Although a recent study suggests propylthiouracil may be associated with a small increase in congenital malformations,6 it is recommended for women requiring treatment for hyperthyroidism who decline radioactive iodine or thyroidectomy.1 Embryopathy secondary to methimazole use in the first trimester is well established across multiple studies.1

Acknowledgements

The authors would like to thank Sana Ghaznavi MD, Margaret Morris MD and Emmanuel Schaub MD for review of this manuscript.

Footnotes

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. Alexander EK,
    2. Pearce EN,
    3. Brent GA,
    4. et al
    . 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. Thyroid 2017;27:315–89.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Abalovich M,
    2. Alcaraz G,
    3. Kleiman-Rubinsztein J,
    4. et al
    . The relationship of preconception thyrotropin levels to requirements for increasing the levothyroxine dose during pregnancy in women with primary hypothyroidism. Thyroid 2010;20:1175–8.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Garber JR,
    2. Cobin RH,
    3. Gharib H,
    4. et al
    .; American Association of Clinical Endocrinologists and American Thyroid Association Task-force on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 2012;22:1200–35.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Plowden TC,
    2. Schisterman EF,
    3. Sjaarda LA,
    4. et al
    . Subclinical hypothyroidism and thyroid autoimmunity are not associated with fecundity, pregnancy loss, or live birth. J Clin Endocrinol Metab 2016;101:2358–65.
    OpenUrlCrossRef
  5. ↵
    1. Negro R,
    2. Schwartz A,
    3. Stagnaro-Green A
    . Impact of levothyroxine in miscarriage and preterm delivery rates in first trimester thyroid antibody-positive women with TSH less than 2.5 mIU/L. J Clin Endocrinol Metab 2016;101:3685–90.
    OpenUrlPubMed
  6. ↵
    1. Andersen SL,
    2. Olsen J,
    3. Wu CS,
    4. et al
    . Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 2013;98:4373–81.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 189 (28)
CMAJ
Vol. 189, Issue 28
17 Jul 2017
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Managing thyroid disease in women planning pregnancy
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Managing thyroid disease in women planning pregnancy
Jennifer Yamamoto, Lois E. Donovan
CMAJ Jul 2017, 189 (28) E940; DOI: 10.1503/cmaj.170021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Managing thyroid disease in women planning pregnancy
Jennifer Yamamoto, Lois E. Donovan
CMAJ Jul 2017, 189 (28) E940; DOI: 10.1503/cmaj.170021
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Women with pre-conception hypothyroidism often require increased levothyroxine once they are pregnant
    • Women should avoid ingesting levothyroxine with iron- or calcium-containing supplements
    • Rates of conception and live birth are not likely influenced by minor thyroid dysfunction4
    • Women with active Graves disease or toxic adenoma should delay pregnancy until normal thyroid function is established
    • Propylthiouracil is preferred for antithyroid drug treatment before conception
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Methemoglobinemia in a 28-year-old woman treated with dapsone
  • Methemoglobinemia caused by sodium nitrite overdose
  • Fixed drug eruption
Show more Practice

Similar Articles

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2022, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire